Merck’s Keytruda may just be on its way to earlier use in head and neck cancer, an area where it once faced some questions. On Wednesday, the New Jersey drugmaker said that … Continue Reading Merck’s Keytruda shores up head and neck case with first-line trial win
Known for curing US President Jimmy Carter’s cancer, Keytruda continues to benefit many other cancer patients. The inventors told us their story, from the drug’s early days to their current … Continue Reading Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug”
Bristol-Myers Squibb is locked in some pretty big marketing battles—but it’ll have to soldier on without its commercial leader. On Monday, the New Jersey drugmaker said EVP and chief commercial officer … Continue Reading Bristol-Myers Squibb commercial chief Gordon jumps ship ahead of key Opdivo launch
July can be a notoriously slow period for U.S. Food and Drug Administration (FDA) activity, and this year is no different. There are only five PDUFA dates scheduled for the month, and … Continue Reading FDA Action Alerts: Lannett, Indivior, Insys and Progenics
Tally another win for Bristol-Myers Squibb’s immunotherapy combination. Wednesday, the New Jersey drugmaker said its Opdivo-Yervoy pairing grabbed an FDA approval in patients with rare colon cancers that have progressed despite other … Continue Reading Bristol-Myers Squibb’s Opdivo-Yervoy combo wins right to challenge Merck’s Keytruda in rare cancer
In the immuno-oncology world, all eyes have been on the market battle playing out in the lucrative lung cancer arena. But with its latest data, breast cancer leader Roche is bringing … Continue Reading Roche eyes next-generation breast cancer crown with Tecentriq’s triple-negative victory
The combination of Merck & Co’s immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said. An early look at results … Continue Reading Merck’s Keytruda Boosts Response in Hard-to-Treat Lung Cancer
Sanofi was a spectator during the last wave of cancer breakthroughs. The French drugmaker is counting on its first new tumor drug in seven years to help make it a … Continue Reading Sanofi Plots Cancer Comeback With First New Drug in Years
At the American Society of Clinical Oncology (ASCO) annual meeting over the weekend, Merck’s Keytruda continued its winning streak. In data presented at the meeting, the cancer immunotherapy was shown … Continue Reading Merck’s Keytruda continues its string of blockbuster results, but BMS’ Opdivo still leads in sales
CHICAGO—Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations. And Monday at the American Society of Clinical Oncology annual … Continue Reading ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?
Oncology DTC advertising has soared in recent years, thanks to new drugs and mechanisms of action. (Syneos Health) As more oncology treatments have flooded the market, so has cancer DTC … Continue Reading New drugs, new money: Surge in cancer DTC ads follows wave of I-O debuts
While Humira held its ad spending crown yet again in May, Latuda jumped up to knock Lyrica from the No. 2 spot it’s held for the past few months. Sunovion … Continue Reading In May TV spending, Sunovion jumps to 2nd, but AbbVie easily keeps top spot
CHICAGO—Merck’s Keytruda already boasts a standalone approval for lung cancer patients who haven’t been treated before, so long as their tumors bear high levels of the PD-L1 biomarker. But it … Continue Reading ASCO: Merck’s solo Keytruda wins again, but might just leave room for competition
The field of genetics has long been an object of global fascination, beginning with Mendel’s pea plant experiments in the 19th century and peaking when the human genome was sequenced … Continue Reading The Next Generation of Genetic Medicine: A Review of Epigenetics
Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much of it is hype? The pipelines of biotech and pharma are filling up with combination therapies … Continue Reading Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?